CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.13B, above the global median of $1.15B
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.70%
Annual Rate
CNY 0.60Paid annual
Payout Ratio
27.6%Sustainable
Last Ex-Dividend
Jun 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.38BCNY2.13B · vs all stocks (USD)
Trailing P/E
87.93xvs Biotechnology peers
Revenue (TTM)
887.21MCNY131.57M · vs all stocks (USD)
Profit Margin
19.30%vs Biotechnology peers
Beta
0.6320xvs all stocks
52-Week Change
51.72%vs all stocks
Market Capitalization
14.38BCNY2.13B · vs all stocks (USD)
Enterprise Value
14.80BCNY2.19B · vs all stocks (USD)
Trailing P/E
87.93xvs Biotechnology peers
Forward P/E
43.41xvs Biotechnology peers
Price to Sales (TTM)
17.28xvs Biotechnology peers
Price to Book (MRQ)
5.66xvs Biotechnology peers
Enterprise to Revenue
16.68xvs Biotechnology peers
Enterprise to EBITDA
81.87xvs Biotechnology peers
Gross Margin
90.35%vs Biotechnology peers
Profit Margin
19.30%vs Biotechnology peers
Operating Margin
25.64%vs Biotechnology peers
Return on Assets (TTM)
2.87%vs Biotechnology peers
Return on Equity (TTM)
6.42%vs Biotechnology peers
Revenue (TTM)
887.21MCNY131.57M · vs all stocks (USD)
Revenue per Share (TTM)
5.38CNYUpdated Aug 19, 2026Quarterly Revenue Growth
26.30%vs Biotechnology peers
Gross Profit (TTM)
743.92MCNY110.32M · vs all stocks (USD)
EBITDA (TTM)
225.58MCNY33.45M · vs all stocks (USD)
Net Income (TTM)
171.25MCNY25.40M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
14.00%vs Biotechnology peers
Operating Cash Flow (TTM)
362.22MCNY53.72M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-119.88MCNY-17.78M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6000CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.70%vs all stocks
Payout Ratio
27.55%vs Biotechnology peers
Revenue
838.12MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
74.13MCNYFY2025 · Dec 31, 2025Gross Profit
763.99MCNYFY2025 · Dec 31, 2025Operating Income
196.96MCNY29.21M · vs all stocks (USD)
Pre-tax Income
169.32MCNYFY2025 · Dec 31, 2025Income Tax Expense
4.48MCNYFY2025 · Dec 31, 2025Net Income
164.84MCNYFY2025 · Dec 31, 2025EBIT
172.01MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
308.01MCNYFY2025 · Dec 31, 2025Research & Development
184.17MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
149.27MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.18MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
50.08MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.69MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.9889CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.9886CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
167.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
167.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
164.84MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
724.32KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
78.32MCNYFY2025 · Dec 31, 2025Free Cash Flow
-125.56MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
311.64MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
164.84MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-10.79MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
74.15MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-149.88MCNYFY2025 · Dec 31, 2025Capital Expenditures
-203.87MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.47BCNYFY2025 · Dec 31, 2025Sale of Investments
2.36BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-320.14MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
55.28MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-87.46MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-85.55MCNYFY2025 · Dec 31, 2025Other Financing Charges
-61.69MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-179.42MCNYFY2025 · Dec 31, 2025Shares Outstanding
167.18MSharesUpdated Aug 19, 2026Float Shares
91.12MSharesUpdated Aug 19, 2026% Held by Insiders
49.58%vs all stocks
% Held by Institutions
14.54%vs all stocks
Total Cash (MRQ)
1.31BCNY194.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.87CNYUpdated Aug 19, 2026Total Debt (MRQ)
82.55MCNY12.24M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0306xvs Biotechnology peers
Current Ratio (MRQ)
13.30xvs Biotechnology peers
Book Value per Share (MRQ)
16.16CNYUpdated Aug 19, 2026Total Assets
3.01BCNY446.33M · vs all stocks (USD)
Total Current Assets
1.79BCNYFY2025 · Dec 31, 2025Total Liabilities
351.90MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.22BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
158.04MCNYFY2025 · Dec 31, 2025Total Current Liabilities
193.86MCNYFY2025 · Dec 31, 2025Cash
311.25MCNYFY2025 · Dec 31, 2025Cash Equivalents
635.58MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
946.83MCNYFY2025 · Dec 31, 2025Other Short-term Investments
398.79MCNYFY2025 · Dec 31, 2025Accounts Receivable
135.33MCNYFY2025 · Dec 31, 2025Inventory
263.74MCNYFY2025 · Dec 31, 2025Accounts Payable
84.71MCNYFY2025 · Dec 31, 2025Short-term Debt
18.62MCNYFY2025 · Dec 31, 2025Other Current Liabilities
250.96KCNYFY2025 · Dec 31, 2025Long-term Debt
67.78MCNYFY2025 · Dec 31, 2025Common Stock (Book)
167.18MCNYFY2025 · Dec 31, 2025Retained Earnings
402.09MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.66BCNY394.14M · vs all stocks (USD)
52-Week Low
35.87CNYUpdated Aug 19, 202652-Week High
95.88CNYUpdated Aug 19, 202652-Week Change
51.72%vs all stocks
Beta
0.6320xvs all stocks
50-Day MA
52.00CNYUpdated Aug 19, 2026200-Day MA
50.83CNYUpdated Aug 19, 2026Avg 10-Day Volume
21.23MSharesUpdated Aug 19, 2026Avg 30-Day Volume
11.77MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
1.04CNYUpdated Aug 19, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.13B, above the global median of $1.15BNotable
Market cap (USD): 2,132,328,468.771Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Jinyu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
HitGen Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Lontium Semiconductor Corp.
5 interpretationsMinimal Tax and Interest DragCash Backing With Revenue And Income StreaksRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Zozo, Inc.
4 interpretationsCash Backing With Revenue And Income StreaksRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Anhui XDLK Microsystems Co., Ltd.
5 interpretationsMinimal Tax and Interest DragCash Backing With Revenue And Income StreaksRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated